Kalaris reports positive Phase 1a TH103 data, $118M cash, net loss $43.4M in 2025

Kalaris Therapeutics, Inc.

Phase 1a in nAMD showed mean 10-letter BCVA gain, 129µm CST improvement, ~95% intraretinal fluid reduction.
TH103 plasma Cmax 27-51 fold lower than approved anti-VEGF agents; no DLTs or serious AEs observed.
Cash, equivalents and marketable securities $118.0M as of Dec 31, 2025; funding into Q4 2027.
Net loss $43.4M for 2025 vs $69.2M in 2024; R&D expense $30.8M, G&A $15.4M.
Completed $50.0M oversubscribed private placement in Dec 2025; Phase 1b/2 preliminary data expected 1H 2027.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Kalaris Therapeutics, Inc. reported the year ended December 31, 2025 results: net income net loss was $43.4 million.

Period: the year ended December 31, 2025
Net income: net loss was $43.4 million
Result: reported results

Exact text from the filing

On March 17, 2026, Kalaris Therapeutics, Inc. (the “Company”) issued a press release announcing the Company’s financial results for the year ended December 31, 2025.

View on SEC.gov

59 earnings releases filed in the last 30 days. Browse all earnings releases →

Kalaris Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-109437

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.